Biotechnology
Latest news, analysis, and insights from ASX biotechnology companies
Vitrafy Life Sciences Reports Strong US Army Platelet Preservation Results
Vitrafy Life Sciences announces 94% post-thaw platelet recovery with 3% DMSO no-wash protocol, independent validation for frozen platelets.
Latest Stories
TrivarX Engages Beyond Drug Development to Progress Stabl-Im Safety Trial
TrivarX engages Beyond Drug Development to push Stabl-Im Phase 1 safety trial, targeting H2 2026 start and data for regulatory progress.
AFT Pharmaceuticals Targets Minimum $300m Revenue After Record Earnings
AFT Pharmaceuticals targets over $300m revenue in FY27 after record FY26 earnings; Australasia core, expanding international hubs.
Nyrada Announces Preclinical Oncology Efficacy for Xolatryp and US Patent Allowance
Nyrada reports strong preclinical Xolatryp efficacy in liver cancer and a US patent allowance, highlighting a ~39% boost vs doxorubicin alone.
OncoSil Medical Secures TGA Approval in Australia for Pancreatic Cancer Device
OncoSil Medical wins TGA approval for OncoSil device to treat unresectable LAPC; ARTG-listed, enabling Australian launch as manufacturing scales up.
Mach7 Technologies Lands New US Customer AMRADNET on 5-Year Deal
Mach7 wins US AMRADNET deal worth A$1.7M, 5-year ARR; deployment cut to 45 days, signaling accelerated growth post-transformation.
BCAL Diagnostics Expands National Access to Early Cancer Detection Blood Tests
BCAL Diagnostics expands access to early cancer blood tests by embedding GP referral forms in major clinical software; launches EarlyDetection telehealth.
Island Pharmaceuticals Strengthens Biodefence Engagement for Galidesivir Advancement
Island Pharmaceuticals strengthens US biodefence push with new adviser Mark Herzog, MC2 roles, and Galidesivir progress toward FDA Animal Rule trials.
Algorae Pharmaceuticals Expands AI Drug Combination Pipeline with Multi-Anchor AOS2 Program
Algorae expands AI drug-combo pipeline with AOS2: 18 anchors, 478k+ synergy predictions across cell lines; stock set for AI-driven discovery boost.
Racura Oncology Advances CPACS Trial to Next Dose Level
Racura Oncology advances RC220 CPACS trial to 80mg/m2 as SRC clears Cohort 2; updated cardioprotection protocol; A$19.38m cash runway to CY2027.
Argenica Therapeutics Establishes Expert Committee to Advance Phase 2b Stroke Trial
Argenica Therapeutics forms Clinical Advisory Committee to accelerate ARG-007 Phase 2b stroke trial.
Anteris Technologies Global Starts US PARADIGM Trial Enrolment
Anteris starts US PARADIGM enrolment; US$320m funding boosts cash to US$283m as Q1 loss widens; CMS coverage boosts TAVR prospects.